Streetbeat News

ALX

Alexander's, Inc.

Industry

REIT - Retail

Alexander's, Inc. is a real estate investment trust which has seven properties in the greater New York City metropolitan area.

Open

215.00

Mkt cap

1.1B

Volume

9.9K

High

216.00

P/E Ratio

25.06

52-wk high

251.63

Low

212.22

Div yield

0.08

52-wk low

184.76

ALX Oncology Holdings Inc. will release its Q4 and full year 2024 financial results on March 6, 2025, before the market opens.

Portfolio Pulse from

February 27, 2025 | 1:15 pm

ALX Oncology Holdings Inc. will host a virtual R&D Day on March 5, 2025, to discuss advancements in their cancer treatment therapies.

Portfolio Pulse from

February 18, 2025 | 1:15 pm

Alexander's (ALX) reported Q4 funds from operations (FFO) of $4.06 per share, surpassing the Zacks Consensus Estimate of $3.71 per share. However, this is a decrease from the $4.99 per share reported a year ago.

Portfolio Pulse from

February 10, 2025 | 4:45 pm

Alexander's, Inc. (NYSE: ALX) has declared a regular quarterly dividend of $4.50 per share, payable on February 28, 2025, to stockholders of record on February 18, 2025.

Portfolio Pulse from

February 05, 2025 | 6:15 pm

Alexander's, a REIT, has seen a decline in its stock price due to rising US 10-year Treasury yields. The company reported a decrease in FFO for Q3 2024 compared to the previous year. Despite a strong cash position, upcoming 2025 debt maturities present a challenge.

Portfolio Pulse from

January 26, 2025 | 3:30 am

ALX Oncology Holdings, Inc. announced the grant of an inducement stock option to its new CFO, Harish Shantharam, for 600,000 shares as part of his employment agreement, in accordance with Nasdaq rules.

Portfolio Pulse from

January 22, 2025 | 9:15 pm

Alexander's, Inc. will release its fourth quarter and full year earnings on February 10, 2025, before the NYSE opens.

Portfolio Pulse from

January 22, 2025 | 6:00 pm

ALX Oncology Holdings Inc. will host a virtual event to discuss updated data from their ASPEN-06 Phase 2 trial on January 23, 2025. The trial evaluates the CD47-blocker evorpacept in patients with HER2-positive advanced gastric or gastroesophageal junction cancer.

Portfolio Pulse from

January 21, 2025 | 10:15 pm

ALX Oncology Holdings Inc. will present updated results from its Phase 2 ASPEN-06 clinical trial of Evorpacept for HER2-positive gastric cancer at the 2025 ASCO Gastrointestinal Cancers Symposium.

Portfolio Pulse from

December 18, 2024 | 1:15 pm

ALX Resources Corp. has received shareholder approval for its acquisition by Greenridge Exploration Inc. through a court-approved plan of arrangement.

Portfolio Pulse from

December 02, 2024 | 9:30 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.